Skip to main content
. 2021 Apr 13;12:650708. doi: 10.3389/fimmu.2021.650708

Figure 1.

Figure 1

Baricitinib delays and attenuates the symptoms of experimental autoimmune encephalomyelitis (EAE) in mice. Mice were injected with MOG35-55 peptide to establish the EAE model and received an injection of either baricitinib or vehicle. Day 0 is EAE induction. (A) The clinical symptom scores of the mice in the different groups after EAE induction. In the baricitinib-treated groups, the clinical signs were remarkably mild. The clinical scores were remarkably better in the baricitinib-treated groups than in the control group from day 10 to 30. (B) Baricitinib delayed the onset of disease in the baricitinib-treated groups. (C) The mean score for mice in each group was recorded every day over a 30 d period. Baricitinib improved the mean clinical score in mice with EAE. (D) The mean cumulative clinical score of vehicle-treated mice was significantly greater than that of baricitinib-treated mice (sum of scores = 30 d). Quantitative data are the mean ± SEM. *p < 0.05; n = 8 per group. SEM, standard error of the mean.